The Swiss Group for Clinical Cancer Research, led by Dr. Florian Strasser of the
The palliative trial will utilize a handheld device known as the Electronic Monitoring of Symptoms and Syndromes Associated with Advanced Cancer (E-MOSAIC) and will monitor patient symptoms in an effort to improve communication between doctors and patients. Additionally, the trial will determine whether the E-MOSAIC tool is helpful when planning patient treatment.
This trial is a controlled, randomized and longitudinal study and will occur over a six-week period. An estimated 24 doctors will oversee the participants. The Swiss Group for Clinical Cancer Research is seeking a total of 192 malignant mesothelioma patients to join the study.
In order to be considered for this trial, patients must be 18 years or older and in the advanced stages of mesothelioma. Potential participants must also be undergoing continuous weekly or biweekly palliative cancer treatment at the time of enrollment in the trial.
The National Cancer Institute (NCI) clinical trial identification number for this particular study is NCT00477919. Those interested in participating must contact Dr. Strasser at florian.strasser@kssg.ch or 41-71-494-1111. Further information regarding the participant requirements may be found at clinicaltrials.gov.
The
The
